首页> 外文期刊>BMC Nephrology >Parvovirus B19 infection and kidney injury: report of 4 cases and analysis of immunization and viremia in an adult cohort of 100 patients undergoing a kidney biopsy
【24h】

Parvovirus B19 infection and kidney injury: report of 4 cases and analysis of immunization and viremia in an adult cohort of 100 patients undergoing a kidney biopsy

机译:Parvovirus B19感染和肾损伤:肾脏活检的100例患者成人群组中的4例和免疫和病毒血症分析报告

获取原文
获取外文期刊封面目录资料

摘要

The seroprevalence of human Parvovirus B19 (PVB19) is 70–85% in adults worldwide. PVB19 is the etiologic agent of the fifth disease, is a cause of aplastic anemia, and can be associated with kidney injury. We aimed to describe the cases of 4 patients with kidney injury related to PVB19 primary infection, and to evaluate the seroprevalence of PVB19 and the incidence of PVB19 primary infection in patients undergoing a native kidney biopsy. Cases of PVB19 infection with kidney injury were reviewed from the archives of the department of Nephrology. A systematic screening of anti-PVB19 IgG and IgM antibodies and viral DNA was performed in sera from 100 consecutive patients with a kidney biopsy in 2017–2018. The 4 patients with PVB19 infection-associated kidney disease displayed: one lupus-like glomerulonephritis (GN) without lupus auto-antibodies, one minimal change disease with tubular necrosis, one secondary hemolytic and uremic syndrome and one membrano-proliferative GN. In the 100 patients biopsied, 67 had elevated anti-PVB19 IgG, among whom 8 had elevated IgM, without circulating viral DNA, without any particular renal pathological pattern. One additional patient showed a seroconversion at the time of kidney biopsy, which revealed a class V lupus nephritis. PVB19 primary infection can be associated with different kidney diseases. The seroprevalence of PVB19 among patients with a kidney biopsy is similar to the overall population, and primary infection is rarely documented (1%) after systematic screening. Whether PV19 is nephrotoxic, or triggers renal endothelial injury and immune activation, remains to be elucidated.
机译:人Parvovirus B19(PVB19)的Seroprevalence在全球成年人中的70-85%。 PVB19是第五疾病的病因试剂,是一种增生性贫血的原因,并且可以与肾损伤有关。我们的旨在描述4例肾脏损伤患者与PVB19初级感染有关的病例,评价PVB19的SEROPREVALING和PVB19初级感染的发病率为肾脏活检的患者。肾脏归档审查了肾损伤PVB19感染的病例。在2017 - 2018年的肾活检的连续患者中,在血清中进行了系统筛选抗PVB19 IgG和IgM抗体和病毒DNA。 4例患有PVB19感染相关的肾病患者显示:一种狼疮般的肾小球肾炎(GN)没有狼疮自动抗体,一种最小的变化疾病,具有管状坏死,一种二次溶血性和尿毒症综合征和一种膜增殖性GN。在100名患者中,67例升高了抗PVB19 IgG,其中8个升高的IgM,无循环病毒DNA,没有任何特定的肾病理模式。另一位患者在肾脏活检时显示血清转换,揭示了V型狼疮性肾炎。 PVB19原发性感染可以与不同的肾脏疾病有关。肾脏活检患者中PVB19的SEROPREVALING类似于整体群体,系统筛查后很少记录原发性感染(1%)。 PV19是否是肾毒性,或触发肾内皮损伤和免疫激活,仍有待阐明。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号